Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous CD19-targeting CAR T Cells for Refractory B Cell Malignancy

NCT02963038 is registered in ClinicalTrials.gov with Hebei Senlang Biotechnology Inc., Ltd. as lead sponsor.

NCT NCT02963038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02963038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous CD19-targeting CAR T Cells for Refractory B Cell Malignancy
Lead sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 30, 2016
Completion date
June 30, 2021
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell leukemia, b-cell lymphoma